ストックスクリーナーアプリを入手
69.21
0.01%
0.010
アフターアワーズ：
69.21
前日終値:
$69.20
開ける：
$69.12
24時間の取引高:
299.66K
Relative Volume:
1.03
時価総額：
$1.48B
収益：
$486.82M
当期純損益:
$18.78M
株価収益率:
84.40
EPS:
0.82
ネットキャッシュフロー:
$100.45M
1週間 パフォーマンス:
+6.28%
1か月 パフォーマンス:
+7.55%
6か月 パフォーマンス:
+15.12%
1年 パフォーマンス:
+5.70%
1日の値動き範囲:
$68.64
$70.48
1週間の範囲:
$64.75
$70.48
52週間の値動き範囲:
$52.50
$70.48
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
名前
Ani Pharmaceuticals Inc
セクター
電話
(218) 634-3500
住所
210 MAIN STREET WEST, BAUDETTE, MN
ANIP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
69.21 | 1.48B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-14 | 開始されました | Jefferies | Buy |
| 2025-03-12 | 開始されました | JP Morgan | Overweight |
| 2024-12-11 | 開始されました | Leerink Partners | Outperform |
| 2024-10-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-15 | 開始されました | CapitalOne | Overweight |
| 2023-08-22 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2022-09-07 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-02 | 開始されました | Truist | Buy |
| 2020-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
| 2019-05-10 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 繰り返されました | Canaccord Genuity | Buy |
| 2017-07-31 | 開始されました | Canaccord Genuity | Buy |
| 2017-02-22 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 開始されました | Raymond James | Strong Buy |
| 2016-05-24 | ダウングレード | Standpoint Research | Buy → Hold |
| 2015-11-13 | 開始されました | Standpoint Research | Buy |
| 2015-09-28 | アップグレード | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-04 | 繰り返されました | ROTH Capital | Neutral |
| 2015-07-31 | 繰り返されました | Oppenheimer | Outperform |
| 2015-07-15 | 繰り返されました | ROTH Capital | Neutral |
| 2015-06-23 | 繰り返されました | Oppenheimer | Outperform |
| 2015-05-18 | 繰り返されました | ROTH Capital | Neutral |
| 2015-05-06 | 繰り返されました | Oppenheimer | Outperform |
| 2015-04-10 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 繰り返されました | ROTH Capital | Buy |
| 2015-02-18 | 繰り返されました | Oppenheimer | Outperform |
すべてを表示
Ani Pharmaceuticals Inc (ANIP) 最新ニュース
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Ani Pharmaceuticals Sr. VP sells $27,583 in stock By Investing.com - Investing.com Canada
Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
ANI Pharmaceuticals (ANIP) Set for Potential Earnings Beat - GuruFocus
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - GlobeNewswire
ANI Pharmaceuticals Reveals Q1 2025 Earnings Date: Key Executive Insights Coming May 9 - Stock Titan
Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO - TradingView
ANI Pharmaceuticals at RBC Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com Canada
Is The Options Market Predicting A Spike In ANI Pharmaceuticals (ANIP) Stock? - Barchart.com
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
ANI Pharmaceuticals To Present At RBC Capital Markets Conference; Webcast At 7:45 AM ET - Nasdaq
Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree - Yahoo Finance
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewswire
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio - TradingView
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross? - Zacks Investment Research
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech
ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - MarketScreener
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewswire
ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com
ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia
ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq
ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com India
ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha
ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com
ANI Pharmaceuticals Completes $17.25 Million Buyout of Royalty Obligation for ILUVIEN and YUTIQ - Nasdaq
ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And Yutiq -March 18, 2025 at 06:55 am EDT - Marketscreener.com
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® - GlobeNewswire
Jefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy Recommendation - Nasdaq
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock - Investing.com India
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock By Investing.com - Investing.com South Africa
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
ANI Pharma rises on expanded US approval for eye-disease drug - TradingView
ANI Pharmaceuticals Says FDA Approves Expanded Label for Iluvien -March 14, 2025 at 07:23 am EDT - Marketscreener.com
Jefferies Initiates Coverage on ANI Pharmaceuticals With Buy Rating, $80 Price Target - Marketscreener.com
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label - GlobeNewswire
ILUVIEN Scores Major FDA Win: Now Treats Two Serious Eye Conditions - StockTitan
JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World
Ani Pharmaceuticals Inc (ANIP) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
0.80%
大文字化:
|
ボリューム (24 時間):